ELVN-001
Chronic Myeloid Leukemia (CML)
Key Facts
About Enliven Therapeutics
Enliven Therapeutics is a clinical-stage biotech company advancing a pipeline of small molecule kinase inhibitors designed to overcome key limitations of existing cancer therapies. The company leverages a team of seasoned drug hunters with proven track records in discovering and commercializing oncology drugs, including multiple FDA-approved therapies. Enliven's strategy focuses on developing highly selective inhibitors that address resistance mechanisms, improve safety, and penetrate the central nervous system to treat brain metastases. With a lead program in CML showing promising early data and a clear clinical development roadmap for 2026, the company is positioned to advance multiple precision oncology candidates.
View full company profileAbout Enliven Therapeutics
Enliven Therapeutics is a clinical-stage biotech company advancing a pipeline of small molecule kinase inhibitors designed to overcome key limitations of existing cancer therapies. The company leverages a team of seasoned drug hunters with proven track records in discovering and commercializing oncology drugs, including multiple FDA-approved therapies. Enliven's strategy focuses on developing highly selective inhibitors that address resistance mechanisms, improve safety, and penetrate the central nervous system to treat brain metastases. With a lead program in CML showing promising early data and a clear clinical development roadmap for 2026, the company is positioned to advance multiple precision oncology candidates.
View full company profileTherapeutic Areas
Other Chronic Myeloid Leukemia (CML) Drugs
| Drug | Company | Phase |
|---|---|---|
| TERN-701 | Terns Pharmaceuticals | Phase 1 |
| Imatinib | Natco Pharma | Approved |